Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of this investigational
drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small
cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got
worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act
on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Phase:
Phase 2
Details
Lead Sponsor:
Criterium, Inc.
Collaborators:
Academic Thoracic Oncology Medical Investigators Consortium Ariad Pharmaceuticals Duke University Georgetown University Ohio State University Takeda University of Colorado, Denver University of Pittsburgh University of Texas Southwestern Medical Center Vanderbilt University